Aptose Biosciences Inc. (TSE:APS – Free Report) (NASDAQ:APTO) – Equities research analysts at HC Wainwright issued their FY2024 EPS estimates for Aptose Biosciences in a research report issued to clients and investors on Wednesday, November 20th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will earn ($2.51) per share for the year. The consensus estimate for Aptose Biosciences’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Aptose Biosciences’ Q4 2024 earnings at ($0.49) EPS.
Aptose Biosciences Stock Performance
Shares of APS opened at C$0.25 on Monday. The company has a quick ratio of 5.41, a current ratio of 0.80 and a debt-to-equity ratio of 670.80. The company has a 50-day simple moving average of C$0.50 and a 200-day simple moving average of C$0.82. Aptose Biosciences has a 52-week low of C$0.19 and a 52-week high of C$3.90. The company has a market capitalization of C$4.44 million, a PE ratio of -0.04 and a beta of 1.36.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Articles
- Five stocks we like better than Aptose Biosciences
- 3 Small Caps With Big Return Potential
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- What is the Nasdaq? Complete Overview with History
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
